Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease

1 Jul 2024

Abstract excerpt

BACKGROUND: Fibrosis-4 (FIB4) is a recommended noninvasive test to assess hepatic fibrosis among patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we used FIB4 trajectory over time (ie, "slope" of FIB4) as a surrogate marker of liver fibrosis progression and examined if FIB4 slope is associated with clinical and genetic factors among individuals with clinically defined MASLD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Associations and Epidemiology
Share to Liver Disease Diagnosis and Treatment
Share to Liver Diseases and Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38967582
DOI: 10.1097/hc9.0000000000000487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver diseasePMID 38967582Read ↗

Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD.Semantic proximity Read ↗

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with Metabolically Dysfunction Associated Steatotic Liver DiseaseSemantic proximity Read ↗

Metabolic and Clinical Heterogeneity in MASLD Risk Stratification: Independent Effects of Body Mass Index and Fib-4 on Cirrhosis, and Clinical Implications of Noninvasive Score Discordance in a Veteran CohortSemantic proximity Read ↗

Decoding MASLD Progression: A Molecular Trajectory-Based Framework for Modelling Disease DynamicsSemantic proximity Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Genetic risk factors for MASLD/MASH and cardiovascular disease in elderly individuals.Semantic proximity Read ↗

GCKR genetic variants and circulating FGF21 define a metabolic risk signature in Metabolic-associated Steatotic Liver diseaseSemantic proximity Read ↗

AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case-control studySemantic proximity Read ↗

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.Semantic proximity Read ↗

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.